Compound: Preladenant
SMILES: o1c(-c2nn3c(nc4c(c3n2)cnn4CCN5CCN(c6ccc(OCCOC)cc6)CC5)N)ccc1
InChIKey: DTYWJKSSUANMHD-UHFFFAOYSA-N
Synonyms: Preladenant, 377727-87-2, SCH-420814, Sch 420814, SCH420814, MK-3814, 950O97NUPO, DTXSID90191219, 7H-Pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-5-amine, 2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-, preladenantum, RefChem:868474, DTXCID50113710, 4-(furan-2-yl)-10-(2-(4-(4-(2-methoxyethoxy)phenyl)piperazin-1-yl)ethyl)-3,5,6,8,10,11-hexaazatricyclo(7.3.0.0^(2,6))dodeca-1(9),2,4,7,11-pentaen-7-amine, UNII-950O97NUPO, MFCD17167056, 2-(Furan-2-yl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)piperazin-1-yl)ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, CHEMBL240624, 2-(Furan-2-yl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)piperazin-1-yl)-ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 5-Amino-2-(2-furanyl)-7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine, 4-(furan-2-yl)-10-[2-[4-[4-(2-methoxyethoxy)phenyl]piperazin-1-yl]ethyl]-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,11-pentaen-7-amine, Preladenant [USAN:INN], C25H29N9O3, 2-(Furan-2-yl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)piperazin-1-yl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-5-amine, 2-(Furan-2-yl)-7-(2-{4-[4-(2-methoxyethoxy)phenyl]piperazin-1-yl}ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 2-(Furan-2-yl)-7-[2-[4-[4-(2-methoxyethoxy)phenyl]piperazin-1-yl]ethyl]-7H-pyrazolo[4,3-E][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, PRELADENANT [INN], Preladenant (USAN/INN), PRELADENANT [USAN], Preladenant(SCH420814), PRELADENANT [WHO-DD], Preladenant(SCH420814)?, GTPL5614, orb1302982, SCHEMBL2856554, GLXC-07617, EX-A1325, BDBM50202986, s6910, AKOS016006028, CS-0999, DB11864, FP27156, SB36921, NCGC00378857-01, NCGC00378857-02, 2-(2-Furanyl)-7-[2-[4-[4-(2-methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, AC-28199, DA-42600, DS-14327, HY-10889, SY031359, NS00072631, D09717, L021041, Q7240024, BRD-K46290096-001-01-1, 2-furan-2-yl-7-(2-{4-[4-(2-methoxy-ethoxy)-phenyl]-piperazin-1-yl}-ethyl)-2,7-dihydro-3H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-ylamine, 2-furan-2-yl-7-(2-{4-[4-(2-methoxy-ethoxy)-phenyl]-piperazin-1-yl}-ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-ylamine, 4-(2-furyl)-10-[2-[4-[4-(2-methoxyethoxy)phenyl]piperazin-1-yl]ethyl]-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,11-pentaen-7-amine, 4-(furan-2-yl)-10-[2-[4-[4-(2-methoxyethoxy)phenyl]piperazin-1-yl]ethyl]-3,5,6,8,10,11-hexazatricyclo[7.3.0.0^{2,6]dodeca-1(9),2,4,7,11-pentaen-7-amine
Theoretical properties:
molecular_formula: C25H29N9O3
molecular_weight: 503.6 g/mol
exact_mass: 503.23933582 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 10
rotatable_bond_count: 9
heavy_atom_count: 37
topological_polar_surface_area: 125 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
chembl: PRELADENANT is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Preladenant (developmental code name SCH-420814) is a drug that was developed by Schering-Plough which acts as a potent and selective antagonist of the adenosine A2A receptor. It was being researched as a potential treatment for Parkinson's disease. Positive results were reported in Phase II clinical trials in humans, but it did not prove itself to be more effective than a placebo during Phase III trials, and so was discontinued in May 2013.
The drug has very high affinity for the A2A receptor (<1 nM) and shows more than 1,000-fold selectivity for the A2A receptor over the other adenosine receptors.
Preladenant shows pro-motivational effects in animals and reverses tetrabenazine-induced motivational deficits. Other A2A receptor antagonists, including istradefylline, Lu AA47070, MSX-3, and MSX-4, have also shown such effects. These agents may be useful in the treatment of motivational disorders in humans. Accordingly, istradefylline has been reported to reduce apathy, anhedonia, fatigue, and depression in people with Parkinson's disease.